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Abstract: Background: The limited form of Granulomatosis with Polyangiitis (GPA), formerly known as Wegener’s 
Granulomatosis (WG) primarily involves the head and neck region, including the orbit, but is often a diagnostic 
challenge, particularly as it commonly lacks positive anti-neutrophil cytoplasm antibody (ANCA) titres or classical 
features on diagnostic orbital biopsies. The purpose of this study was to relate biopsy findings with clinical outcome 
and to determine which histopathological features are predictive of a clinical diagnosis of GPA. Methods: Retrospec-
tive case series of 234 patients identified from the database of the UCL Institute of Ophthalmology Department of 
Eye Pathology as having had orbital biopsies of orbital inflammatory disorders performed between 1988 and 2009. 
Clinical records were obtained for the patients and analysed to see whether patients had GPA or not, according to 
a standard set of diagnostic criteria (excluding any histopathological findings). Biopsy features were then correlated 
with the clinical diagnosis in univariate and multivariate analyses to determine factors predictive of GPA. Results: 
Of the 234 patients, 36 were diagnosed with GPA and 198 with other orbital pathologies. The majority of biopsies 
were from orbital masses (47%). Histology showed a range of acute and chronic inflammatory pictures in all biop-
sies, but the presence of neutrophils (P<0.001), vasculitis (P<0.001), necrosis (P<0.001), eosinophils (P<0.02) and 
macrophages (P=0.05) were significantly associated with a later clinical diagnosis of GPA. In a multivariate analysis, 
only tissue neutrophils (OR=3.6, P=0.01) and vasculitis (OR=2.6, P=0.02) were independently associated with GPA, 
in contrast to previous reports associating eosinophils and necrosis with the diagnosis. Conclusions: Neutrophil, 
eosinophil and macrophage infiltration of orbital tissues, together with vasculitis and necrosis, are all associated 
with a clinical diagnosis of GPA, but only neutrophil infiltration and vasculitis are independently associated with this 
diagnosis. These features may assist in the establishing the diagnosis of limited GPA among patients with early 
orbital disease, particularly in the absence of positive serum ANCA titres.
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Introduction
Granulomatosis with Polyangiitis (GPA), former-
ly known as Wegener’s granulomatosis (WG), is 
a systemic small-vessel vasculitis that is char-
acterised by necrotising granulomatous inflam-
mation affecting the renal, pulmonary, upper 
airways and ocular systems, and is associated 
with circulating anti-neutrophil cytoplasm anti-
bodies (ANCA) [1]. The initial symptoms of GPA 
are observed in the head and neck region in 
some 95% of patients, but making the diagno-
sis at this stage is often extremely challenging. 
GPA remains limited to ENT and ocular involve-
ment in some patients, but can involve other 
organs, such as the lungs and kidneys [2], with 
severe consequences for the patient. Important 
issues in the management of GPA include both 
prediction of disease progression and the side-
effects of the drugs required to treat active dis-
ease. Early diagnosis of limited GPA is useful, 
as it enables earlier introduction of the appro-
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priate immunosuppressive therapy, presum-
ably reducing the risk of local progression of 
the disease and of involvement of other organs, 
including the kidney, after which the prognosis 
dramatically worsens [3]. 
Ocular involvement occurs in 50-60% of 
patients and is the presenting feature in 8-16%, 
with severe ocular morbidity occurring as a 
complication of both localised and systemic 
GPA [4]. Orbital involvement occurs in approxi-
mately half of all patients with GPA, and may 
lead to orbital bone destruction and loss of 
vision from contraction and fibrosis around the 
optic nerve, despite treatment and resolution 
of inflammation [5]. Ocular features of GPA 
include scleritis, which can be necrotising and 
bilateral, and which can pose a major threat to 
the integrity of the globe. Nevertheless, the 
diagnosis of ocular GPA is particularly difficult 
as its clinical manifestations often overlap with 
other inflammatory conditions such as sarcoid-
osis and idiopathic inflammatory orbital disor-
ders. In addition, in the limited form of GPA, 
anti-neutrophil cytoplasm antibody (ANCA) 
titres are positive in only 50-65% of patients [6, 
7]. 
Although the histopathological findings are 
often diagnostic for GPA in renal disease [8, 9], 
this is not the case for orbital and upper air-
ways disease, with classic findings being pres-
ent in less than a third of patients, and fewer 
than this in recent-onset disease [10, 11]. 
Indeed, the histological features of GPA can 
mimic other forms of idiopathic orbital inflam-
mation such as sarcoidosis, idiopathic 
inflammatory orbital disorders and lymphoid 
hyperplasia.
The histological features of orbital GPA are 
diverse and can include any of the following: 
granulomatous foci, collagen deposition, necro-
sis, nuclear dust, plasma cells and an infiltrat-
ing eosinophilic response [12]. The latter has 
been suggested to predict disease progression 
[13], analogous to the suggestion that, in renal 
biopsies in GPA, an increase CD8+ cells might 
also predict and increase in disease activity 
[14]. These descriptions are drawn from rela-
tively small numbers of patients, and, as yet, 
there has not been a study which has system-
atically analysed a large number of orbital biop-
sies. We therefore performed such a retrospec-
tive investigation for a consecutive case series 
in which we examined histopathology reports of 
all patients who had undergone orbital biopsies 
for orbital inflammatory disorders over a period 
of 21 years, and related this to their clinical out-
comes. To our knowledge, this is the first study 
of its kind.
Methods
The study was approved by the Moorfields & 
Whittington Research Ethic Committee and 
was a retrospective study of all patients who 
had undergone orbital or adnexal biopsy for 
orbital inflammatory disease at Moorfields Eye 
Hospital over 21 years. All patients who had 
undergone an orbital or adnexal biopsy between 
1988 and 2009 were identified from the UCL 
Institute of Ophthalmology Department of Eye 
Pathology Database. The biopsy reports were 
reviewed, and the cell types and tissue respons-
es documented qualitatively as present or 
absent. Cell types noted included neutrophils, 
eosinophils, plasma cells, multinucleated giant 
cells, macrophages and mast cells; tissue 
responses assessed included necrosis, 
sclerosis, lymphoid follicles, nuclear debris and 
granulomas.
A comprehensive review of the clinical notes 
was next performed to obtain information on 
patient demographics and clinical data includ-
ing the final clinical diagnosis, orbital signs and 
symptoms, ocular signs and symptoms, other 
organ involvement, ANCA status, treatment and 
duration of follow up. Patients were classified 
as having clinical features consistent with a 
diagnosis of GPA if they met any two of the fol-
lowing clinical criteria: (1) Characteristic ocular 
features of GPA; (2) Characteristic ENT, pulmo-
nary, renal or cardiac involvement; (3) Positive 
immunofluorescence for ANCA; (4) Positive 
ELISA for anti-PR3 antibodies. Crucially, histo-
logical findings and diagnosis were excluded 
from the list of diagnostic criteria to avoid con-
founding the study and patients were included 
in the “non-GPA” group if they did not meet the 
above criteria. Systemic and limited GPA were 
defined by the presence or absence of renal or 
lower airway involvement, respectively. Patients 
were also classified as ‘newly-diagnosed’ or 
‘known’ GPA depending on whether their clini-
cal diagnosis had been made prior to the biop-
sy procedure.
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The unpaired student’s T-test and Fisher’s 
exact test were performed to examine differ-
ences between the two groups. Univariate anal-
ysis was performed, including the calculation of 
95% confidence intervals. Multivariate analysis 
was performed to look for any independent 
association of a cellular profile or tissue 
response with the clinical diagnosis of GPA. For 
the multivariate logistic regression analyses, all 
statistically significant variables (P<0.05) from 
the univariate analyses were included. SPSS 17 
and GraphPad Prism 5.01 were used to per-
form the statistical analysis.
Results
Two hundred and thirty-four patients were iden-
tified from the UCL Institute of Ophthalmology 
pathology database as having undergone orbit-
al biopsy for an orbital inflammatory condition 
between 1988 and 2009, and for whom full 
clinical details were available. Of these, 36 
patients fulfilled our criteria for the diagnosis of 
GPA. Diseases in the non-GPA group included 
chronic idiopathic inflammation of the orbit 
(CIIO) in 74/198 patients (37%), lymphoid 
hyperplasia in 16 (8%), sarcoidosis in 13 (7%), 
myositis in 3 (2%), dacroadenitis in 33 (17%), 
and thyroid eye disease in 12 (6%). Patient 
characteristics are included in Table 1, and 
indicate no significant differences between the 
GPA and non-GPA groups. 
Clinical characteristics of orbital GPA
Of the 36 patients in the GPA group, two 
patients (6%) had systemic GPA (that is, with 
renal or lower airways involvement) and 34 
 Table 1. Patient characteristics
GPA (n=36) Non GPA (n=198) P
Age 50.7 ± 3.2 years 50.4 ± 1.2 years 0.92
Gender (M:F) 21:15 (57%:43%) 127:71 (64%:36%) 0.57
Biopsy structures
      -       Orbital mass 20 91 0.29a
      -       Lacrimal gland 8 79
      -       Nasolacrimal/sinonasal 12 31
      -       Extraocular muscle 2 28
      -       Other 3 11
  aP value represents χ2 test of orbital mass vs. other biopsy site for each group
 Table 2. Comparison of cellular profiles
Cell type GPA (%) (n=36)
Not GPA (%) 
(n=198)
Unadjusted Adjusted
OR P OR P
PMN 19 (53%) 30 9 (15%) 5.9 (2.7 – 12.6) <0.0001* 3.9 (1.4 – 11.2) 0.01*
Eosinophil 19 (53%) 62 (31%) 2.5 (1.2 – 5.0) 0.02* 0.7 (0.24 – 1.8) 0.42
Vasculitis 19 (53%) 11 (6%) 19.0 (7.8 – 46.4) <0.0001* 4.8 (1.6 – 14.7) 0.006*
Necrosis 22 (39%) 21 (11%) 5.4 (2.4 – 12.0) <0.0001* 2.4 (0.8 – 6.6) 0.10
Lymphocyte 19 (53%) 113 (57%) 0.8 (0.4 – 1.7) 0.86
Fibrosis 22 (61%) 111 (56%) 1.2 (0.6 – 2.6) 0.72
Macrophage 16 (44%) 55 (28%) 2.1 (1.0 – 4.3) 0.05* 2.0 (0.9 – 4.5) 0.11
Plasma cells 18 (50%) 85 (43%) 1.3 (0.7 – 2.7) 0.47
Giant cells 2 (6%) 23 (12%) 0.4 (0.1 – 2.0) 0.39
Follicles 4 (11%) 34 (17%) 0.6 (0.2 – 1.8) 0.47
Nuclear debris 2 (6%) 6 (3%) 1.9 (0.4 – 9.7) 0.36
Granuloma 12 (33%) 45 (23%) 1.7 (0.8 – 3.7) 0.21
+ve = cells reported present in biopsy; -ve = cells not reported in biopsy; OR = odds ratio; CI = confidence interval; * = statisti-
cally significant difference (P<0.05); % = percentage of patients with positive occurrence of cell type or tissue response 
reported in biopsy within each group.  Adjusted odds ratios are adjusted for all statistically significant variables (P<0.05) from 
the univariate analyses.
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(94%) had limited disease. Seventeen (47%) 
had been diagnosed with GPA before their ocu-
lar symptoms commenced and had received 
treatment in the form of corticosteroids, with or 
without second-line immunosuppression; the 
remaining 19 (53%) had a diagnosis of GPA 
based on their ocular disease. The most com-
mon ocular presentations in the GPA group 
were proptosis (55%), lid swelling (44%) and 
scleritis (32%). Other ocular presentations 
included diplopia, epiphora (nasolacrimal 
block), ocular pain and decreased vision. 
Interestingly, and in agreement with recent 
studies, no patients with limited GPA were 
observed to progress to the systemic form of 
GPA during the duration of this study [15, 16]. 
The duration of follow-up in this study was a 
median 36 months (range 24 to 190 months; 
708 patient-years in total).
Biopsy features predictive of clinical features 
consistent with a diagnosis of GPA
In the univariate analysis, neutrophils, eosino-
phils, vasculitis, macrophages and necrosis 
were present significantly more often in the 
GPA group than in the non-GPA group (Table 2). 
A multivariate analysis, controlling for con-
founding factors, showed that neutrophils and 
vasculitis are independently associated with 
the clinical diagnosis of GPA - with odd ratios of 
3.9 and 4.8 respectively.
Twelve patients were ANCA-positive, 11 were 
ANCA-negative and the remaining 13 patients 
did not have any ANCA levels on record – being 
patients with an established diagnosis of GPA 
prior to their ophthalmic presentation. There 
was a trend for eosinophils (P=0.08) and lym-
phocytes (P=0.09) to be seen more frequently 
in the ANCA-positive group than in the ANCA-
negative group.
Just over a half (19/36) of the patients were 
newly diagnosed with GPA and 17 had a known 
diagnosis of GPA prior to ophthalmic presenta-
tion, including 2 patients with systemic GPA. All 
patients with established GPA had previously 
received, or were still on, immunosuppressive 
treatment. Presumably due to a lack of prior 
treatment, cellular infiltration was greater in 
patients without a prior diagnosis of GPA and 
the changes including the presence of nuclear 
debris and giant cells, both of which were seen 
only in patients without prior therapy.
Discussion
The diagnosis of ophthalmic GPA is difficult, as 
its clinical manifestations often overlap with 
other inflammatory disorders. Furthermore, 
ANCA titres are positive in only 50-65% of such 
patients, and classic histological features are 
also frequently absent from biopsy material; 
this being in contrast to disease affecting other 
organs, such as the kidney [5, 7, 11, 13]. 
Nevertheless, this investigation indicates that 
there are significant differences in the cellular 
and tissue profile in biopsies taken from 
patients who will later be assigned a diagnosis 
of GPA, as compared to other diseases, the 
presence of infiltrating neutrophils and vasculi-
tis being independently associated with a clini-
cal diagnosis of GPA. Biopsies from patients 
with GPA also show many more inflammatory 
cells as compared to other types of lymphocytic 
orbital inflammatory disorders, which reflects 
the tendency to a more fulminant disease with 
GPA. 
Previous studies have suggested that eosino-
phils play a part in the pathogenesis of GPA 
and, in one study, the presence of eosinophils 
in biopsies of patients with limited GPA was 
said to be predictor of disease progression [7]. 
In our study, a univariate analysis did indicate 
significantly more eosinophils in patients with 
GPA, but this was lost when other confounding 
factors were controlled for, suggesting that the 
number of tissue eosinophils might be associ-
ated with disease severity, rather than being 
associated with GPA in particular. 
Nuclear debris is an entity that has recently 
become a subject of interest in GPA and is 
thought to originate from the rupture of nuclei 
of neutrophils in the tissue of patients with 
GPA, possibly as a result of ANCA activity [9, 
12]. In our study, nuclear debris was seen more 
frequently in the GPA group, but this might be 
underrepresented as pathologists may not 
have specifically reported this phenomenon in 
the past; further quantitative evaluation of this 
entity in orbital biopsies would be interesting 
and beneficial. In addition, the efficacy of ritux-
imab in certain patients with GPA implicates a 
role for B cells in the aetiology and perpetua-
tion of disease, and further characterisation of 
these cells at different stages of disease would 
be of interest [5, 17, 18].
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Interestingly, despite the limitation that all 
of the cellular profiles in this study were 
based on histopathological reports, we 
were still able to detect significant differ-
ences in cellular activity between the GPA 
and non-GPA group. Developing a grading 
system for the cellular and tissue profiles 
should provide a clearer picture of cellular 
activity in these orbital biopsies, and there-
by enable a more accurate comparison to 
be made between orbital biopsies. 
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